Pulmonx is a company.
Pulmonx has raised $32.0M across 1 funding round.
Key people at Pulmonx.
Pulmonx has raised $32.0M in total across 1 funding round.
Pulmonx has raised $32.0M in total across 1 funding round.
Pulmonx's investors include HealthCap.
Key people at Pulmonx.
Pulmonx Corporation (Nasdaq: LUNG) is a commercial-stage medical technology company specializing in minimally invasive treatments for severe chronic obstructive pulmonary disease (COPD), particularly emphysema. Its flagship product, the Zephyr® Endobronchial Valve, is a breakthrough FDA-approved device that improves breathing, exercise capacity, and quality of life for patients with hyperinflated lungs by blocking diseased portions via bronchoscopy, without surgery.[1][2][3] The company also offers the Chartis® Pulmonary Assessment System for patient evaluation and the StratX® Lung Analysis Platform, a cloud-based CT analysis tool to identify optimal treatment lobes.[1][2] Serving pulmonologists and patients worldwide in over 25 countries, Pulmonx addresses the unmet need in severe emphysema cases where standard medical management fails, with over 40,000 treatments delivered since 2007 and inclusion in global guidelines like GOLD (Evidence A rating).[1][2][3]
Pulmonx, based in Redwood City, California, and Neuchâtel, Switzerland, emerged as a leader in interventional pulmonology for obstructive lung diseases. The Zephyr Valve received FDA Breakthrough Device designation and pre-market approval in June 2018, recognized for offering bronchoscopic lung volume reduction without surgical risks, providing a significant advantage over standard care.[1][2] Development built on extensive clinical evidence, with over 100 scientific publications including randomized controlled trials, meta-analyses, and cost-effectiveness studies validating its benefits.[2] Early traction came from commercialization in Europe since 2007, leading to widespread adoption as a standard-of-care option in treatment guidelines.[1][2][3]
Pulmonx rides the wave of advancing interventional pulmonology and personalized lung treatments amid rising COPD prevalence—a progressive, irreversible disease affecting millions globally, with emphysema causing severe hyperinflation and disability.[1][2][3] Timing aligns with FDA's Breakthrough recognition in 2018, accelerating adoption as non-surgical alternatives gain traction in respiratory care, supported by guideline endorsements and growing demand for evidence-based devices.[1][2] Market forces like aging populations, increasing emphysema diagnoses, and shifts toward outpatient bronchoscopic procedures favor Pulmonx, influencing the ecosystem by setting standards for lung volume reduction and inspiring hybrid diagnostic-treatment platforms.[1][2][3]
Pulmonx is poised for expanded global adoption of Zephyr Valve therapy, leveraging its proven track record and tools like StratX to penetrate emerging markets and refine patient selection via AI-enhanced imaging. Trends in precision medicine, remote diagnostics, and value-based care will shape growth, potentially boosting procedure volumes as COPD burdens rise. Its influence may evolve by dominating emphysema treatment paradigms, fostering partnerships with health systems, and pioneering next-gen pulmonology innovations—solidifying its role as the go-to for transforming severe lung disease outcomes.[1][2][3]
Pulmonx has raised $32.0M across 1 funding round. Most recently, it raised $32.0M Series C in March 2010.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2010 | $32.0M Series C | HealthCap |
